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needs to be taught in small friendly doses tied to practical problems. Each analysis 
note presented by Doug Gause has sketches drawn by artist Pat Gause.
CONCEPTUAL PAPERS & RESEARCH ON METHODS – Study Design
PMC48
METHODS FOR IDENTIFYING CASE REPORTS OF SUSPECTED ADVERSE 
DRUG REACTIONS: AN EVALUATION OF THE EFFICIENCY OF 
ALTERNATIVE SEARCH STRATEGIES IN MEDLINE AND EMBASE
Michels SL, Ward A, Jones N
United BioSource Corp., Lexington, MA, USA
To illustrate the precision and sensitivity of identifying case reports of adverse events 
(AE) in MEDLINE and EMBASE, eight searching methods were created and applied 
to two systematic reviews of case reports. Search methods included use of indexing 
and text words for synonyms of AE and related terms, as well as drug, disease and 
study design. All eight methods contained the drug and combinations of other search 
strings and ranged from broad to very speciﬁc. Searches were developed for MEDLINE 
and EMBASE; duplicates were removed. Results from each approach were checked 
against a “gold standard” (GS) of case reports previously identiﬁed in two systematic 
reviews (75 anti-TNF agent, 57 baclofen case reports). Sensitivity and precision of 
each method were calculated. The broadest search, using drug terms alone, yielded 
over 11,000 and over 3,600 references for each systematic review topic. Sensitivity 
decreased as search methods became narrower; precision was consistently low (gener-
ally <6%). The search method for drug terms alone had 100% sensitivity for both 
systematic review topics with very low precision (<1.6%). Precision was highest when 
drug, disease, case report and AE were combined for baclofen (15%) with low sensitiv-
ity (26%). Of the GS articles available from MEDLINE, 7% and 18% of anti-TNF 
agent and baclofen case reports respectively were not indexed as case reports. Sensitive 
search methods able to identify relevant case reports are important, but when a sensi-
tive search was constructed, this lead to low precision. A sensitive search method must 
be broad, and search both databases. Precision remains low with each combination 
of approaches, making accurate identiﬁcation of case reports rather labor intensive. 
This illustration demonstrated the extent to which decisions made when developing 
search methods impact the comprehensiveness of reviews. Further work is on-going 
to conﬁrm the generalizability of these ﬁndings to other drugs.
CANCER – Clinical Outcomes Studies
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OBJECTIVES: Therapy-related myelodysplastic syndromes and acute myeloid leuke-
mia (t-MDS/AML) are devastating long-term complications of cancer therapy. Evi-
dence suggests that white blood cell growth factors (CSFs) may increase risk of t-MDS/
AML among patients (pts) receiving chemotherapy, possibly because they stimulate 
the proliferation and differentiation of hematopoietic stem cells and also interfere with 
apoptosis. The purpose of this retrospective study was to evaluate the association 
between CSF use and t-MDS/AML among a large population-based cohort of elderly 
non-Hodgkin’s lymphoma (NHL) pts treated with chemotherapy. METHODS: NHL 
pts were identiﬁed from the Surveillance, Epidemiology, and End Results-Medicare 
database diagnosed from 1992 to 2002 who received chemotherapy within 12 months 
of diagnosis. Pts were followed from their initial chemotherapy until t-MDS/AML 
development, death, or end of study period (December 31, 2006). Kaplan-Meier and 
Cox proportional hazards analyses were used to evaluate the association between CSF 
use and t-MDS/AML. RESULTS: A total of 13,203 pts were identiﬁed. Overall, 40% 
(n = 5,266) received CSF. 272 (5.2%) pts receiving CSF developed t-MDS/AML vs. 
230 (2.9%) who did not receive CSF (log-rank p < 0.0001). In a multivariable Cox 
regression analysis adjusting for gender, histology, stage, comorbidities, chemotherapy 
dates, and chemotherapy agent, CSF use was independently associated with a 53% 
increased risk of t-MDS/AML (HR 1.53; 95% CI 1.26–1.84). A dose-response rela-
tionship was observed, with t-MDS/AML risk increasing by quartile of CSF claims. 
In an evaluation of plausible biologic interactions, we found that pts receiving CSF 
and antimetabolite chemotherapy (n = 1,567 pts) had a 2.5 fold increased risk of 
t-MDS/AML (HR 2.49; 95% CI 1.91–3.26) vs. pts who received neither agent (p-inter-
action = 0.04). CONCLUSIONS: Our ﬁndings suggest that CSF use among elderly 
NHL chemotherapy pts chemo may increase risk of t-MDS/AML, even though abso-
lute risk is low. Future studies are necessary to verify these results and to determine 
the clinical implications of the observed interaction between CSF use and antimetabo-
lite chemotherapy.
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DIABETIC MEDICATIONS AND ITS ASSOCIATION WITH MORTALITY 
IN HOSPITALIZED CANCER PATIENTS
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OBJECTIVES: The effect of diabetes and diabetic medications on the morbidity and 
mortality in hospitalized cancer patients is a serious concern. We examined the asso-
ciation of diabetic medications with the transfer to ICU and inpatient mortality. 
METHODS: Electronic patient records were prospectively collected in 5489 hospital-
izations to UT MD Anderson Cancer Center from May 1st, to July 31st, 2006. For 
each patient demographic, laboratory and pharmacy data were obtained. To observe 
the effect of diabetic medications, we selected only diabetic patients, which were 
36.3% (1991) of the total hospitalization. Descriptive and logistic regression analyses 
were performed. RESULTS: Out of 1991 hospitalizations for diabetic cancer patients, 
ﬁfty seven percent were male, sixty nine percent were White with median age of sixty 
one. These patients were on different diabetic medications and thirty one percent were 
only on sliding scale insulin (SSI).After controlling for socio-demographic variables 
and other medications like chemotherapy, we found cancer patients who were only 
on SSI were more likely to be transferred to intensive care unit (ICU), (OR 2.31, CI: 
1.7–3.2; P < 0.001) and die during hospitalization (OR 1.88, CI: 1.3–2.7; P < 0.001). 
Glucocorticoids administration was also signiﬁcantly associated with inpatients mor-
tality (OR 5.91, CI: 3.5–9.8; (p < 0.00)). CONCLUSIONS: We found strong associa-
tions between the method of administration of insulin (SSI) and transfer to ICU and 
inpatient mortality in cancer patients with diabetes. Drug dosage and administration 
in inpatient settings should be tailored to the need of the patients to optimize the 
medication effect and minimize the side effects.
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OBJECTIVES: Adverse symptom reporting is essential in clinical trials and drug label-
ing to assess and ensure patient safety. The standard approach to collecting adverse 
symptoms in cancer trials is clinician reporting using the Common Terminology 
Criteria for Adverse Events (CTCAE), which rates symptoms based upon descriptive 
clinical criteria. Despite the importance of this information, the reliability of these 
ratings has not been veriﬁed. At Memorial Sloan-Kettering Cancer Center, patients 
are routinely evaluated via CTCAE items by a clinician in an ofﬁce suite, and again 
shortly thereafter by a second clinician in a chemotherapy suite, with no information 
passed between clinicians. METHODS: To measure the reliability of these evaluations, 
a retrospective analysis of medical charts was completed in a sample of 433 patients 
aged 26–91 (M = 62.39; 41.8% male) receiving chemotherapy, who were enrolled in 
an observational study conducted between March 2005 and August 2009. Cancer 
diagnoses included lung (N = 153), prostate (N = 127), and gynecologic (N = 153). 
RESULTS: For the ﬁrst post-chemotherapy visit, intraclass correlation coefﬁcients 
were moderate for fatigue (0.52), dyspnea (0.75), nausea (0.55), vomiting (0.50), 
diarrhea (0.63), constipation (0.48) and neuropathy (0.73). The average time between 
evaluations was 70.42 minutes (range 67.97–72.88). These values were stable over up 
to six subsequent visits and did not differ based on age, gender, or elapsed time 
between evaluations. CONCLUSIONS: Given the short period of time and lack of 
interventions between reporting time points, the most likely cause of this lower than 
expected agreement between different clinicians is limited reliability of clinician report-
ing of this information. This ﬁnding has implications to clinical trials, as it brings into 
question the reliability or accuracy of symptom safety information. The investigators 
are currently evaluating patient-reported outcomes as an alternative and potentially 
more reliable method for collecting this information.
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A SYSTEMATIC REVIEW
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OBJECTIVES: There have been reports which suggest that insulin glargine use may 
contribute to increased cancer risk in some type 2 diabetic populations, in addition 
to the fact that diabetes mellitus is also associated with certain types of cancer. There-
fore, the objective of the present study is to conduct a review of published studies on 
insulins and the risk of cancer in patients with type 2 diabetes and summarize the 
ﬁndings. METHODS: Several databases such as Medline and PubMed were used for 
publication searching. Key words included insulin, tumor, cancer, type 2 diabetes, and 
speciﬁc insulin names such as glargine, lantus, lispro, aspart, etc. Only English lan-
guage literature was considered for articles looking at the increased risk of cancer 
among type 2 diabetic patients using insulins. RESULTS: About 30 articles were 
selected, among those, 4 studies were conducted in humans using secondary database. 
All were historic cohort studies, and three used Cox regression for analysis. Two 
articles established a positive association between cancer incidence and insulin 
glargine, while the other two found no association. Three studies also showed that 
several insulins other than glargine are not associated with an increased risk of cancer. 
